No Data
SymbolStock Name
Latest PriceChg%ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D %Chg10D %Chg20D %Chg60D % Chg120D %Chg250D %Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
US OptionsDetailed Quotes
DCTH240816C10000
- 0.35
- +0.05+16.67%
15min DelayClose Jul 19 15:55 ET
0.35High0.30Low
0.30Open0.30Pre Close15 Volume885 Open Interest10.00Strike Price475.00Turnover102.33%IV25.76%PremiumAug 16, 2024Expiry Date0.00Intrinsic Value100Multiplier25DDays to Expiry0.35Extrinsic Value100Contract SizeAmericanOptions Type0.2860Delta0.1516Gamma23.51Leverage Ratio-0.0151Theta0.0014Rho6.73Eff Leverage0.0075Vega
Intraday
- 5D
- Daily
News
Delcath Systems Solidifies Leadership With Renewed Executive Contracts
Delcath Systems, Inc. (DCTH) Is a Great Momentum Stock: Should You Buy?
Breakeven On The Horizon For Delcath Systems, Inc. (NASDAQ:DCTH)
Delcath Systems Regains Compliance With Nasdaq Audit Committee Composition Requirement
Delcath Systems (DCTH) said Tuesday it has regained compliance with the Nasdaq Stock Market's audit committee composition requirements for continued listing.The company was in noncompliance because
Express News | Delcath Systems Inc Files for Mixed Shelf of up to $150 Mln – SEC Filing
Craig-Hallum Initiates Delcath Systems(DCTH.US) With Buy Rating, Announces Target Price $18
Craig-Hallum analyst Chase Knickerbocker initiates coverage on $Delcath Systems(DCTH.US)$ with a buy rating, and sets the target price at $18.According to TipRanks data, the analyst has a success rate
Comments
$Delcath Systems(DCTH.US$ Delcath Systems Q1 2024 GAAP EPS $(0.45) Beats $(0.47) Estimate, Sales $3.139M Beat $2.187M Estimate
$Delcath Systems(DCTH.US$ Publication of Results from Pivotal FOCUS Study in Metastatic Uveal Melanoma Patients treated with HEPZATO KIT
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
1 MINUTE AGO, 9:00 AM EDT
VIA PR NEWSWIRE
Significantly Higher Overall Response Rate vs Meta-analysis of Historical Controls (36.3% vs. 5.5%)
Other Efficacy Endpoints Include a 73.6% Disease Control Rate with a 7.7% Complete Response Rate
1
$Annovis Bio(ANVS.US$ 22% Ph2/3 data reporting update
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
$Taysha Gene Therapies(TSHA.US$ 21% FY 2023 results
$TFF Pharmaceuticals(TFFP.US$ 14% Clinical programs update
$Jaguar Health(JAGX.US$ 14% Crofelemer commercialization
$Acelyrin(SLRN.US$ 4% Ph1/2 positive data
$Delcath Systems(DCTH.US$ 3% Closes $7M private placement
$Sellas Life Sciences(SLS.US$ 0% Closes $20M offering & private placement
$Immunic(IMUX.US$ 1% Patent notice of allowance
$Nurix Therapeutics(NRIX.US$ 0...
10
1
$Delcath Systems(DCTH.US$ Delcath Systems Announces $7M Private Placement
3
Read more